The potential of human neutrophil peptides in tuberculosis therapy

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 11, 2003, Pages 1027-1032

  Fu, Li M ^a,b  

^a Pac TB/Cancer Res Organization   (United States)

^b Pac TB/Cancer Res Organization   (United States)

Author keywords

Bacterial persistence; Defensin; Drug resistance; Human neutrophil peptide; Mycobacteria; Tuberculosis

Indexed keywords

CHEMOTACTIC FACTOR; DEFENSIN; HUMAN NEUTROPHIL PEPTIDE; OPSONIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERICIDAL ACTIVITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG MECHANISM; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW;

ALPHA-DEFENSINS; ANTI-INFECTIVE AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; NEUTROPHILS; TUBERCULOSIS, PULMONARY;

EID: 0242667895     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
2. Johnson J L, Ellner J J. Adult tuberculosis overview: African versus Western perspectives. Curr Opin Pulm Med 2000; 6: 180-186.
3. McKinney J D, Honer zu Bentrup K, Munoz-Elias E J, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-738.
4. Ganz T, Oren A, Lehrer R I. Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells. Med Microbiol Immunol (Berl) 1992; 181: 99-105.
5. Lehrer R I, Lichtenstein A K, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 1993; 11: 105-128.
6. Ganz T, Lehrer R I. Defensins. Pharmacol Ther 1995; 66: 191-205.
7. Ganz T, Lehrer R I. Antibiotic peptides from higher eukaryotes: biology and applications. Mol Med Today 1999; 5: 292-297.
8. Schutte B C, Mirtos J P, Bartlett J A, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002; 99: 2129-2133.
9. Gabay J E, Scott R W, Campanelli D, et al. Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1989; 86: 5610-5614.
10. Jones D E, Bevins C L. Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett 1993; 315: 187-192.
11. Porter E M, Liu L, Oren A, Anton P A, Ganz T. Localization of human intestinal defensin 5 in Paneth cell granules. Infect Immun 1997; 65: 2389-2395.
12. Liu L, Zhao C, Heng H H, Ganz T. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 1997; 43: 316-320.
13. Valore E V, Park C H, Quayle A J, Wiles K R, McCray P B Jr, Ganz T. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101: 1633-1642.
14. McNamara N A, Van R, Tuchin O S, Fleiszig S M. Ocular surface epithelia express mRNA for human beta defensin-2. Exp Eye Res 1999; 69: 483-490.
15. Harder J, Bartels J, Christophers E, Schroder J M. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
16. Garcia J R, Krause A, Schulz S, et al. Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. Faseb J 2001; 15: 1819-1821.
17. Daher K A, Lehrer R I, Ganz T, Kronenberg M. Isolation and characterization of human defensin cDNA clones. Proc Natl Acad Sci USA 1988; 85: 7327-7331.
18. Kisich K O, Heifets L, Higgins M, Diamond G. Antimycobacterial agent based on mRNA encoding human beta-defensin 2 enables primary macrophages to restrict growth of Mycobacterium tuberculosis. Infect Immun 2001; 69: 2692-2699.
19. Linzmeier R, Michaelson D, Liu L, Ganz T. The structure of neutrophil defensin genes. FEBS Lett 1993; 326: 299-300.
20. Selsted M E, Harwig S S. Purification, primary structure, and antimicrobial activities of a guinea pig neutrophil defensin. Infect Immun 1987; 55: 2281-2286.
21. Miyakawa Y, Ratnakar P, Rao A G, et al. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996; 64: 926-932.
22. Sharma S, Verma I, Khuller G K. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 2000; 16: 112-117.
23. Dubos R J, Hirsch J G. The antimycobacterial activity of a peptide derived from calf thymus. J Exp Med 1954; 99: 55-64.
24. Krensky A M. Granulysin: a novel antimicrobial peptide of cytolytic T-lymphocytes and natural killer cells. Biochem Pharmacol 2000; 59: 317-320.
25. Sparkes R S, Kronenberg M, Heinzmann C, et al. Assignment of defensin gene(s) to human chromosome 8p23. Genomics 1989; 5: 240-244.
26. Linzmeier R, Michaelson D, Liu L, Ganz T. The structure of neutrophil defensin genes. FEBS Lett 1993; 321: 267-273.
27. Fang X M, Shu Q, Chen Q X, et al. Differential expression of alpha- and beta-defensins in human peripheral blood. Eur J Clin Invest 2003; 33: 82-87.
28. Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298: 995-1000.
29. Gera J F, Lichtenstein A. Human neutrophil peptide defensins induce single strand DNA breaks in target cells. Cell Immunol 1991; 138: 108-120.
30. Sharma S, Khuller G. DNA as the intracellular secondary target for antibacterial action of human neutrophil peptide-I against Mycobacterium tuberculosis H37Ra. Curr Microbiol 2001; 43: 74-76.
31. Paone G, Wada A, Stevens L A, et al. ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proc Natl Acad Sci USA 2002; 99: 8231-8235.
32. Chertov O, Michiel D F, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996; 271: 2935-2940.
33. Chaly Y V, Paleolog E M, Kolesnikova T S, Tikhonov I I, Petratchenko E V, Voitenok N N. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000; 11: 257-266.
34. Lillard J W Jr, Boyaka P N, Chertov O, Oppenheim J J, McGhee J R. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 1999; 96: 651-656.
35. Fomicheva E E, Pivanovich I, Shamova O V, Nemirovich-Danchenko E A. [Glucocorticoid hormones in immunomodulating effect of defensins]. Ross Fiziol Zh Im I M Sechenova 2002; 88: 496-502. [In Russian].
36. Ogata K, Linzer B A, Zuberi R I, Ganz T, Lehrer R I, Catanzaro A. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992; 60: 4720-4725.
37. Kisich K O, Higgins M, Diamond G, Heifets L. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002; 70: 4591-4599.
38. Edwards D, Kirkpatrick C H. The immunology of mycobacterial diseases. Am Rev Respir Dis 1986; 134: 1062-1071.
39. Brown A E, Holzer T J, Andersen B R. Capacity of human neutrophils to kill Mycobacterium tuberculosis. J Infect Dis 1987; 156: 985-989.
40. Jones G S, Amirault H J, Andersen B R. Killing of Mycobacterium tuberculosis by neutrophils: a nonoxidative process. J Infect Dis 1990; 162: 700-704.
41. Silva M T, Silva M N, Appelberg R. Neutrophil-macrophage cooperation in the host defence against mycobacterial infections. Microb Pathog 1989; 6: 369-380.
42. Ganz T. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 1987; 55: 568-571.
43. Sharma S, Verma I, Khuller G K. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 2001; 45: 639-640.
44. Territo M C, Ganz T, Selsted M E, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989; 84: 2017-2020.
45. Welling M M, Hiemstra P S, van den Barselaar M T, et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest 1998; 102: 1583-1590.
46. Ashitani J, Mukae H, Hiratsuka T, Nakazato M, Kumamoto K, Matsukura S. Elevated levels of alpha-defensins in plasma and BAL fluid of patients with active pulmonary tuberculosis. Chest 2002; 121: 519-526.
47. Peschel A, Jack R W, Otto M, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001; 193: 1067-1076.
48. Miller S I, Pulkkinen W S, Selsted M E, Mekalanos J J. Characterization of defensin resistance phenotypes associated with mutations in the phoP virulence regulon of Salmonella typhimurium. Infect Immun 1990; 58: 3706-3710.
49. Lichtenstein A, Ganz T, Selsted M E, Lehrer R I. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 1986; 68: 1407-1410.
50. Lichtenstein A K, Ganz T, Selsted M E, Lehrer R I. Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins. Cell Immunol 1988; 114: 104-116.
51. Lichtenstein A K, Ganz T, Nguyen T M, Selsted M E, Lehrer R I. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J Immunol 1988; 140: 2686-2694.